Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease.

Pharmacoepidemiology and Drug Safety
Usha GungabissoonNicholas Galwey

Abstract

To estimate the risk of dyskinesia and impulse control disorders (ICDs) in patients with Parkinson's disease (PD) prescribed ropinirole prolonged-release (R-PR) compared to those prescribed immediate-release dopamine agonists (IR-DA) as monotherapy. PD patients initiating R-PR or IR-DA as monotherapy between 2008 and 2013 were identified on the Clinical Practice Research Datalink. The cohorts were propensity score matched on a 1:1 basis. The incidence of dyskinesia and ICD in each treatment cohort and the incidence rate ratios were calculated. Adherence to medication and time to levodopa initiation were also evaluated. We identified 341 patients in each treatment cohort after propensity score matching. The baseline characteristics were generally comparable. Dyskinesia incidence in R-PR and IR-DA cohorts was 2.98 (95% CI: 0.74-11.9) and 3.93 (95% CI: 0.98-15.7) per 1000 person-years, respectively (incidence rate ratio of R-PR vs ID-DA: 0.76, 95% CI: 0.11-5.38). Less than five cases of ICD were identified and all occurred in the IR-DA cohort. The patients in the R-PR cohort remained on treatment for a significantly longer duration than those in the IR-DA cohort (682 days vs 444 days; P < .0001) and had greater adherence to the me...Continue Reading

References

Oct 26, 2000·Brain : a Journal of Neurology·A Schrag, N Quinn
Jul 13, 2006·Archives of Neurology·Daniel WeintraubMatthew B Stern
Sep 27, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserAnthony E Lang
Dec 10, 2008·CNS Drugs·Juliane Weber, Gillian M Keating
Dec 19, 2009·Parkinsonism & Related Disorders·Jee-Young LeeBeom S Jeon
Mar 24, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Stephen Ku, Graham A Glass
May 12, 2010·Archives of Neurology·Daniel WeintraubAnthony E Lang
May 13, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Ray L WattsUNKNOWN 228 Study Investigators
Jul 6, 2010·Parkinsonism & Related Disorders·J C SharmaG Linazasoro
Sep 17, 2013·Annals of Neurology·C Warren Olanow, Anthony H V Schapira
Jan 18, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Pedro J Garcia-RuizIgnacio Mahillo Fernandez
Feb 5, 2014·Expert Opinion on Drug Safety·Fabrizio StocchiMargherita Torti
Apr 24, 2014·JAMA : the Journal of the American Medical Association·Barbara S Connolly, Anthony E Lang
Dec 3, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Peter A LeWitt
Dec 3, 2014·Parkinsonism & Related Disorders·Yoshikuni MizunoUNKNOWN Rotigotine Trial Group
Dec 17, 2014·CNS Drugs·Naveed Malek, Donald G Grosset
Jun 8, 2015·International Journal of Epidemiology·Emily HerrettLiam Smeeth
Jun 15, 2016·Journal of Physiotherapy·Caroline E RoffmanGarry T Allison
Oct 19, 2016·Lancet Neurology·Alberto Ascherio, Michael A Schwarzschild
Feb 24, 2017·Lancet Neurology·Valerie VoonPierre-Olivier Fernagut
Aug 5, 2017·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Charity J Morgan
Sep 2, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Marie Grall-BronnecGaëlle Challet-Bouju
Jul 5, 2018·Journal of Neural Transmission·Tai N TranDaniel D Truong
Nov 9, 2018·Neurology·Pierpaolo TurcanoRodolfo Savica

❮ Previous
Next ❯

Citations

May 26, 2020·CNS & Neurological Disorders Drug Targets·Andrew SchneiderYoussef Sari

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.